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introduction: To date, no reliable prognostic biological marker for all squamous cell 
carcinoma located in different subsites of the head and neck region has been identified 
and used in daily routine. In line with our previous studies, in which we showed a role of 
glutathione and associated enzymes as potential biological markers, we investigated the 
relationship between GPx1 and prognosis of head and neck squamous cell carcinoma.
Methods: The association between GPx1 and patient and tumor related factors were 
investigated in 87 pretreatment biopsies from head and neck cancer patients treated by 
(chemo)radiation. Moreover, the influence of GPx1 expression on outcome parameters 
was assessed.
results: A significant difference was found in the T-stage between the low and high- 
expressing GPx1 groups. About 75% of the T3–T4 tumors were considered GPx1 
low-expressing tumors, while low GPx1 expression was only seen in 25% of the T1–T2 
tumors. There was also a significant difference found between the groups when looking 
at the different tumor sites. Local control, locoregional control, disease-free survival, 
and overall survival were the same in both groups. All these results indicate that GPx1 
expression does not influence the radiotherapy response nor survival.
Keywords: oxidative stress status, head and neck cancer, glutathione peroxidase, prognostic significance
inTrODUcTiOn
Cancer of the head and neck region represent the fifth most common form of cancer and caused 
350,000 deaths per year (1, 2). Tumors of the head and neck have strong links to oxidative damage 
and oxidative stress, with tobacco and alcohol clearly defined as major etiologic factors.
So far, no reliable prognostic biological marker for the squamous cell carcinoma located in 
different subsites of the head and neck region has been identified and used in daily routine. In 
accordance with other authors, we believe that potential markers can be found among the parameters 
of oxidative stress (3, 4).
Therefore, in line with our previous studies pointing at the role of glutathione and associated 
enzymes as potential biological markers (5, 6), we have investigated relationships between GPx1 and 
prognosis of head and neck squamous cell carcinoma (HNSCC).
TaBle 2 | scoring categories according to the percentages of gPx1 
positive cells in the tumor.
Percentage of stained cells scoring
<10 0
10–25 1
25–50 2
50–75 3
>75 4
TaBle 1 | scoring categories according to the intensity of gPx1 labeling 
in the tumor.
intensity score
Low 1
Medium 2
High 3
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By reducing hydrogen peroxide at the expense of oxidizing 
GSH to its disulfide form, GSSG, GPx1 is a major enzyme of the 
cellular antioxidant armada (3). It is present in cytosolic and 
mitochondrial compartments, but, in some cells, in peroxisomal 
compartments (7). GPx1 has been found to be more effective than 
catalase at protecting the cells again intracellular peroxides under 
many physiological conditions.
GPx1 activity is often compared with glutathione reductase 
activity, which role is to maintain a constant level of GSH from 
GSSG for enzyme activity. Furthermore, GPx1 is highly upregu-
lated during oxidative stress making it a suitable biomarker for 
oxidative stress (8). Therefore, in this retrospective study, we 
investigated the prognostic value of GPx1 expression in head and 
neck cancers.
MaTerials anD MeThODs
study cohort
The study cohort consisted out of 87 HNSCC patients (73 males, 
14 females, median age 58.2  years) who underwent definitive 
radiotherapy or concomitant chemoradiotherapy as primary 
oncological treatment at the University Hospital in Leuven. 
Treatment modality was based on the extent of the disease 
at initial presentation and performance status of the patient. 
Radiotherapy alone was initiated in 31 patients (36%). All patients 
received 72 Gy of radiation; treatment was administered once a 
day, five times a week the first 4 weeks of therapy, the last 2 weeks 
two fractions per day were administered (9). Forty-nine of the 
87 patients (56%) received concomitant chemoherapy based on 
cisplatin 100 mg/m2 week 1 and week 4. Six patients (7%) were 
treated by radiotherapy with concurrent cetuximab. Cetuximab 
was chosen in those patients with contraindications for cisplatin. 
Median follow-up was 5.54 years (4.15–7.67).
The study was performed according to protocols approved 
by the Ethical board of the University Hospitals (Commissie 
Medische Ethiek van de Universitaire ziekenhuizen KULEUVEN), 
and all the patients provided inform consent. Histological exami-
nation of the tumor biopsies indicated squamous cell carcinomas 
in all cases. Human papillomavirus (HPV) and p16 status was 
determined as previously described (10).
immunohistochemistry of Tumor Biopsies
For immunostaining of GPx1 (HPA044758; Sigma-Aldrich), 
routine formalin-fixed paraffin-embedded (FFPE) pretreatment 
tumor tissues, available for 87 HNSCC patients were used. Briefly, 
4-µm FFPE tumor sections were deparaffinized in Ultraclear 
and rehydrated in 100% ethanol. Endogenous peroxidases were 
blocked by using 0.3% H2O2 in Methanol solution. Heat-induced 
antigen retrieval (pH 6) was performed. Immunodetection was 
performed with EnVision HRP Anti-Rabbit secondary antibody 
and peroxidase/DAB kit (Dako). Sections were counterstained 
with hematoxylin. Scoring of GPx1 was performed by multiplying 
the intensity (Table 1) and percentage of tumor cells (Table 2). 
High GPx1-expressing tumors were defined by a high-intensity 
score (3) and high-scoring categories (>3) according to the 
percentage of GPx1 positive tumoral cells (>50%).
statistical analysis
Differences in GPx1 high- and low-expression groups were 
analyzed using the Chi-square test in case of categorical predic-
tors, whereas one-way ANOVA was used in cases of continuous 
predictors. Former smokers are defined as patients who stopped 
smoking longer than 1 year prior to the date of diagnosis. Local 
control (LC) and locoregional control (LRC) were defined as 
the time between the start of treatment and the date of local or 
locoregional recurrence. Time between the start of treatment and 
disease recurrence or death expressed the disease-free survival 
(DFS). Overall survival (OS) was determinated by the time 
between the initial treatment and death of any cause. The survival 
curves were generated and calculated by using, respectively, the 
Kaplan–Meier method and the log-rank test. All analyses were 
performed using the Statistica software version 12, and all test 
were considered significant when p ≤ 0.05.
resUlTs
A total of 87 pretreatment patient tumor samples were stained for 
GPx1 (Figure 1). The baseline patient and tumor characteristics 
according to GPx1 expression are summarized in Table 3. Twenty-
eight percent of the total amount of patients (24 out of 87) showed 
a high expression of GPx1. The majority of patients (72%) showed 
low expression levels of GPx1. The age, treatment modality, and 
HPV/p16 status did not differ between the two different groups. 
No relation was found between GPx1 expression and smoking 
history. Also, no significant differences were found in nodal 
status between the two groups. However, a significant negative 
correlation between T-status and GPx1 (r = −0.23; p = 0.028) was 
noted. About 75% of the T3–T4 tumors were considered GPx1 
low-expressing tumors, while low GPx1 expression was only seen 
in 25% of the T1–T2 tumors. Also, significant differences were 
found between the GPx1 groups and different tumor sites.
Assessment of GPx1 expression and outcome parameters such 
as LC (Figure 2A), DFS (Figure 2B), OS (Figure 2C), and LRC 
(Figure 2D) did not result in significant differences.
All these results indicate that GPx1 expression does not influ-
ence the radiotherapy response nor the survival.
TaBle 3 | Patient and tumor characteristics by gPx1 expression.
Data gPx1 high gPx1 low all patients p-Value
No of patients No. % No. % No. %
24 28 63 72 87
Gender NS
Male 19 79 54 86 73 72
Female 5 21 9 14 14 28
Age, years NS
Median (range) 58.6 (46–76) 58.0 (43–78) 58.2 (43–78)
Nodal status NS
N0/N1 8 33 25 40 33 38
N2/N3 16 67 38 60 54 62
Tumor status p = 0.028
T1/T2 12 50 16 25 28 32
T3/T4 12 50 47 75 59 68
Disease stage NS
I–II 1 4 2 3 3 3
III–IV 23 96 61 97 84 97
Tumor site p = 0.033
Soft palate 1 4 2 3 3 3
Tonsil 8 33 19 30 27 30
BOT/vallecula 14 59 19 30 33 37
Pharyngeal wall 0 0 9 15 9 14
Unknown 1 4 14 22 15 16
Human  
papillomavirus (HPV)
NS
HPV negative 15 63 35 56 50 57
HPV positive 5 21 8 13 13 15
Unknown 4 16 20 31 24 28
Treatment NS
RT 8 33 23 36 31 36
RT + cetuximab 1 4 5 8 6 7
RT + CT 15 63 34 54 49 56
Unknown 0 0 1 2 1 1
Smoking history NS
Never 4 17 4 6 8 9
Former 5 21 11 17 16 18
Current 12 50 45 72 57 66
Unknown 3 12 3 5 6 7
p16 NS
Negative 3 12 19 30 22 25
Nuclear 7 29 18 29 25 29
Cytoplasmic 10 42 15 24 25 29
Unknown 4 17 11 17 15 17 
NS, not significant; BOT, base of tongue; RT, radiotherapy; CT, chemotherapy.
FigUre 1 | classification of the gPx1 staining according to intensity 
and the percentage of stained cells. (a) Tumors classified as low levels of 
GPx1. (B) Tumor classified as high levels of GPx1.
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DiscUssiOn
Cancer of the head and neck region and their treatment protocols 
still lack well-established prognostic biological markers (11). It 
is well known that non-HPV-related oropharyngeal cancers and 
HPV-related cancers are distinct entities concerning tumor biol-
ogy and clinical outcome. For oropharyngeal cancers, HPV is a 
well-established prognostic marker to radiotherapy response (10) 
and survival. For non-oropharyngeal cancers, the HPV status is 
not of prognostic significance (12, 13) and, currently, there is no 
general guidance to adapt treatment strategies to HPV status. 
In line with previous publications, we believe that parameters 
of oxidative stress could offer useful potential markers (3, 4). 
Previously, we confirmed this hypothesis by demonstrating that 
a significant redox imbalance in head and neck cancer patients 
could offer a prognostic value (14).
Moreover, we reported a strong correlation between the 
contents of oxidized and reduced glutathione (GSSG/GSH) 
in tumors and the nodal status of our head and neck patients. 
A lower ratio GSSG/GSH was observed in tumor tissue of N0 
patients, while a higher ratio GSSG/GSH was determined in posi-
tive node patients. This might suggest that high GSSH/GSH ratio 
tumors have a more aggressive phenotype caused by the oxidative 
stress, leading to a tendency to more local spread. Furthermore, 
compared to patients who showed high levels of oxidative stress 
ratio GSSH/GSH, patients with lower ratio GSSG/GSH showed 
lower risk of locoregional recurrence of their tumor after treat-
ment. This again suggests that tumors with high-oxidative stress 
status are more aggressive.
These data lead us to extent our research by checking other 
components of the cellular antioxidant armada. In line with 
previous studies pointing to the role of glutathione-associated 
enzymes as potential markers, we have investigated relationships 
between GPx1 and prognosis of HNSCC.
Based on preclinical and clinical studies on glutathione 
peroxidase levels in tumors (15, 16), glutathione peroxidase, an 
important member of the defensive machinery against oxidative 
stress, was investigated.
No correlation was found between HPV status and the expres-
sion of GPx1. Furthermore, p16 status and localization did not 
differ between the groups of treated patients. A possible explana-
tion could be the confounding effect of T-status on outcome. 
Our results contrast with the results presented by other authors. 
Williams et al. (17) suggested, in their study, that high risk types 
of human papillomavirus increased the level of reactive oxygen 
species, associated with a decrease of antioxidant enzyme GPx1 
expression. This increased oxidative stress led to higher levels of 
DNA damage.
Furthermore, in contrast with our previous results, no signi-
ficant correlation was found between the tumors expressing GPx1, 
found to be more effective than catalase at removing intra cellular 
peroxides under many physiological conditions, and the nodal 
status. By contrast, Han et al. (18) found that high GPx1-expressing 
tumors were associated with extensive lymph node metastasis.
However, a significant correlation between T-status and GPx1 
expression in tumors (p =  0.03) was found. The patients with 
tumors showing a low GPx1 expression had more tumors staged 
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FigUre 2 | association between gPx1 expression and outcome parameters. (a) Correlation between GPx1 expression and outcome with local control  
(LC) as endpoint. On the y-axis is the percentage of patients with LC displayed, and on the x-axis is the time in years displayed. (B) Correlation between GPx1 
expression and outcome with disease-free survival (DFS) as endpoint. On the y-axis is the percentage of patients with DFS displayed, and on the x-axis is the  
time in years displayed. (c) Correlation between GPx1 expression and outcome with overall survival (OS) as endpoint. (D) Correlation between GPx1 expression  
and outcome with locoregional control as endpoint. On the y-axis is the percentage of patients with OS displayed, and on the x-axis is the time in years displayed.  
p Values are determined by log-rank tests.
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T3–T4. Moreover, we observed a significant correlation between 
tumors expressing GPx1 and the tumor localization. The patients 
with low GPx1-expressing tumors had more tumors located at 
the tonsil.
The function of GPx1 is to promote migration, proliferation, 
and tumor cell invasion, conditioning a potential not yet defined 
prognostic role, in cancer patients (19). The results published by 
Han et al support these findings, showing that expression of GPx1 
was related to good outcome (p = 0.03) in patients with human 
gastric adenocarcinoma.
In hepatocellular carcinoma, Zmorzynski et  al. (20) found 
that high GPx1-expressing tumors were correlated with a shorter 
survival time as in patients with prostate cancer.
Moreover, high GPx1-expressing tumors could be respon-
sible for cisplatin resistance as observed in esophageal cancer 
cell lines (21). Similarly, Zhao et al. observed that GPx1 may 
serve as a molecular marker for monitoring bladder cancer 
recurrence (22). In patients with gastric cancer, low expressed 
GPx1 tumors were associated with aggressiveness and poor 
survival (23).
Interestingly, our results suggest the absence of the prognostic 
value of GPx1 expression in head and neck cancers. No signifi-
cant differences were found in any of the other characteristics: LC, 
LRC, DFS, and OS. A possible explanation would be that a small 
biopsy of the tumor does not represent the whole tumor, taking 
into account the issue of tumor heterogeneity. Moreover, since, 
we only had the availability of small paraffin-embedded biopsies, 
only one immunohistochemistry staining for GPx1 could be 
performed. Several other markers of the oxidative stress pathway 
could be investigated (24). New research into others markers of 
oxidative stress seems valuable.
To determine the cellular antioxidant capacity, next to other 
isoforms of glutathione peroxidase as GPx4, the expression 
of other important antioxidant enzymes, such as manganese 
superoxide dismutase and its isoform SOD2 will be of interest as 
proven in preliminary animal studies (25).
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To elucidate the potential clinical significance of GPx1 
obser ved in other solid tumors, large studies, analyzing multiple 
glutathione-associated enzymes in addition to GPx1, are needed.
cOnclUsiOn
After determining the levels of oxidative stress in 87 HNSCC 
patients, significant clinical differences were found between 
patients expressing high level of GPx1 and patients expressing 
low levels of GPx1. A significant negative correlation between 
T-stage and GPx1 expression in tumors (p =  0.03) was found. 
The patients with tumors showing a low GPx1 expression had 
more tumors staged T3–T4. Moreover, we observed a significant 
correlation between tumors expressing GPx1 and the tumor 
localization. The patients with low-expressing GPx1 tumors had 
more tumors located at the tonsil. Interestingly, no significant 
differences were found in any of the outcome characteristics: LC, 
LRC, DFS, and OS, suggesting the absence of the prognostic value 
of GPx1 expression is HNSCC.
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